{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:42:03Z","timestamp":1759585323487,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.eururo.2020.10.005","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T21:44:50Z","timestamp":1602884690000},"page":"657-658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to Alexander Andreev-Drakhlin, Jianjun Gao, Arlene Siefker-Radtke. Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. Eur Urol 2021;79:655\u20136"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6216-1913","authenticated-orcid":false,"given":"Jeffrey J.","family":"Leow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yew Lam","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven L.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bego\u00f1a P.","family":"Valderrama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2020.10.005_bib0005","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.eururo.2020.08.033","article-title":"Levelling the evidence: a comparison of neoadjuvant and adjuvant treatment for upper tract urothelial carcinoma","volume":"79","author":"Andreev-Drakhlin","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.10.005_bib0010","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","article-title":"Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy","volume":"79","author":"Leow","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.10.005_bib0015","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2020.10.005_bib0020","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1200\/JCO.2018.36.6_suppl.407","article-title":"Results of POUT: a phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC)","volume":"36","author":"Birtle","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.10.005_bib0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00345-012-0939-5","article-title":"Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma","volume":"31","author":"Fajkovic","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2020.10.005_bib0030","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.juro.2010.09.110","article-title":"Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer","volume":"185","author":"Sonpavde","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.10.005_bib0035","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.eururo.2017.06.012","article-title":"Systematic review of immune checkpoint inhibition in urological cancers","volume":"72","author":"Rijnders","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.10.005_bib0040","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1200\/JCO.2006.10.4323","article-title":"End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group","volume":"25","author":"Sargent","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.10.005_bib0045","first-page":"123101","article-title":"Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: pooled analysis of individual patient data from randomised controlled trials","author":"Ronellenfitsch","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2020.10.005_bib0050","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/jjco\/hyv136","article-title":"Prediction of renal function after nephroureterectomy in patients with upper tract urothelial carcinoma","volume":"45","author":"Hashimoto","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.10.005_bib0055","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bju.12597","article-title":"Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma","volume":"114","author":"Kaag","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.10.005_bib0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000353652","article-title":"Predictive factors for impaired renal function following nephroureterectomy in upper urinary tract urothelial cell carcinoma","volume":"92","author":"Rodriguez Faba","year":"2014","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2020.10.005_bib0065","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.urolonc.2018.12.002","article-title":"Preoperative multiplex nomogram for prediction of high-risk nonorgan-confined upper-tract urothelial carcinoma","volume":"37","author":"Petros","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2020.10.005_bib0070","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.urolonc.2019.06.009","article-title":"Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma","volume":"37","author":"Freifeld","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2020.10.005_bib0075","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","article-title":"European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update","volume":"79","author":"Roupr\u00eat","year":"2021","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382030782X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382030782X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:09:20Z","timestamp":1759583360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382030782X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S030228382030782X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2020.10.005","relation":{},"ISSN":["0302-2838"],"issn-type":[{"type":"print","value":"0302-2838"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to Alexander Andreev-Drakhlin, Jianjun Gao, Arlene Siefker-Radtke. Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. Eur Urol 2021;79:655\u20136","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2020.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2020.08.033","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2020.07.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}